First Person Ltd.
(Note: This IPO was revamped to a stock-only deal in an SEC filing on Oct. 14, 2022; it was initially planned as a unit deal.)
First Person Ltd., a company incorporated in Alberta, Canada, is a holding company. The Company conducts its business and operations through its wholly owned operating subsidiaries: First Person, Inc., a Delaware corporation (“FP, Inc.”), and TruMed Limited, a Jamaican company limited by shares (“TruMed”). We intend to compete in the following three markets:
Psilocybin, the naturally occurring drug found in psychedelic mushrooms, is currently a Schedule I controlled substance under the U.S. Controlled Substances Act of 1970 (the “CSA”) and is currently an illegal substance in the State of Washington and all other U.S. states. Therefore, production and research of psilocybin requires approvals from federal and state authorities, which may be granted in the sole discretion of such authorities. Even with the necessary approvals, production and research of psilocybin may be subject to quotas or other restrictions set by federal or state authorities. If we obtain the requisite approvals from all applicable state and federal governmental authorities, including the Washington State Department of Health (“WDOH”) and the DEA, then we intend to build out our naturally derived psychedelic mushroom supply chain in the United States in full compliance with state and federal laws. Psilocybin is not an illegal drug under Jamaica’s Dangerous Drugs Act, 1948 (the “Jamaica Drug Act”). Unlike mushrooms that contain psilocybin, functional mushrooms and nutraceuticals are fully legal in the United States. We do not intend to market any of our products for medical use.
Our goal is to activate the full potential of human cognition through mushroom innovation. We believe that First Person, despite its early stage of development, is building a resilient foundation for long-term growth, and we believe we have positioned ourselves for success in the brain health and wellness markets through our innovative product formulations and production processes.
(Note: First Person Ltd. revised its IPO to a stock-only deal – dropping the warrants from its prospectus – in an S-1/A filing dated Oct. 14, 2022, in which it also disclosed its IPO’s terms: 1.1 million shares (1,103,448 shares) at $6.75 to $7.75 to raise $7.98 million. The assumed IPO price is $7.25, the mid-point of its range. First Person Ltd. filed its S-1 on May 5, 2022; the company filed confidential IPO paperwork on Dec. 30, 2021.)
|Industry:||Medicinal Chemicals & Botanical Products|
|Address||1840, 444 – 5th Ave., SW Calgary, AB, T2P 2T8|
|Phone Number||(587) 577-9261|
|View Prospectus:||First Person Ltd.|
|Revenues||$0.05 mil (last 12 months)|
|Net Income||$-3.84 mil (last 12 months)|
|Price range||$6.75 - $7.75|
|Est. $ Volume||$8.0 mil|
|Manager / Joint Managers||EF Hutton|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|